Category: Acceleron

Acceleron investors dig their heels in on Merck takeover bid

October 22, 2021 Auto Bot 0

Activist investors are pushing back against Merck & Co’s recent $11.5 billion deal to acquire Acceleron Pharma, arguing that its $180-per-share offer seriously undervalues the […]

PharmaShots Weekly Snapshots (September 27 – October 01, 2021)

October 1, 2021 Auto Bot 0

BMS Reports EMA’s Validation of MAA for Relatlimab and Nivolumab as 1L Treatment for Unresectable or Metastatic Melanoma Published: Oct 1, 2021 | Tags: BMS, […]

PharmaShots’ Key Highlights of Third Quarter 2021

September 30, 2021 Auto Bot 0

The third quarter of 2021 highlights the approvals, clinical data & acquisitions. The new alliance observed in third quarter includes AzurRx signed a reverse triangular […]

Merck to Acquire Acceleron for ~$11.5B

September 30, 2021 Auto Bot 0

Shots: Merck to acquire Acceleron for $180/share in cash making a total equity value of ~$11.5B representing a premium of 2.6% to the stock’s closing […]

Merck confirms $11.5bn Acceleron takeover deal

September 30, 2021 Auto Bot 0

After days of speculation, Merck & Co confirmed today that it has agreed to acquire Acceleron Pharma $1.5 billion, setting up what could be one […]

Rumour mill says Acceleron is speeding towards $11bn sale

September 26, 2021 Auto Bot 0

US biopharma company Acceleron is the next company heading for a takeover by a big pharma group – according to a Bloomberg report citing people […]

EHA21: Study raises BMS’ hopes for Reblozyl in less severe disease

June 14, 2021 Auto Bot 0

Bristol-Myers Squibb has taken another step towards achieving its blockbuster hopes for beta thalassaemia-associated anaemia therapy Reblozyl, after hitting the target in a phase 2 […]

PharmaShots Weekly Snapshots (Mar 29 – Apr 02, 2021)

April 2, 2021 Auto Bot 0

Pfizer and BioNTech Report Results of BNT162b2 to Prevent COVID-19 Published: Apr 2, 2021 | Tags: Pfizer and BioNTech, Report, Results, BNT162b2, Prevent, COVID-19 Acceleron […]

Acceleron Presents Results of Sotatercept in P-II PULSAR Trial for the Treatment of Pulmonary Arterial Hypertension, Published in NEJM

April 2, 2021 Auto Bot 0

Shots: The P-II PULSAR trial involves assessing Sotatercept (0.3 mg/kg or 0.3 mg/kg, SC, q3w) vs PBO in 106 patients in a ratio (3:3:4) with […]

PharmaShots Weekly Snapshots (Feb 15- 19, 2021)

February 19, 2021 Auto Bot 0

RedHill Signs a Manufacturing Agreement with Cosmo for Movantik and RHB-204 Published: Feb 19, 2021 | Tags: RedHill, Signs, Manufacturing, Agreement, Cosmo, Movantik, RHB-204 Astellas and […]

Acceleron Signs a License Agreement with Fulcrum for the Identification of Therapies to Treat Pulmonary Diseases

December 31, 2019 Auto Bot 0

Shots: Fulcrum to receive $10M upfront, reimbursement for R&D costs, research, development and commercial milestone of up to $295M for first product commercialized and additional […]